Screener
West Pharmaceutical Services WST Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by West Pharmaceutical Services in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000105770-26-000099
| (in millions, except per share data) | June 30,2026 | December 31,2025 |
|---|---|---|
| Goodwill | 108.7 | 109.9 |
| Intangible assets, net | 6.4 | 7.7 |
| Deferred income taxes | 72.3 | 38.4 |
| Other noncurrent assets | 82.8 | 80.1 |
| Total Assets | $4,076.4 | $4,270.0 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $252.7 | $253.7 |
Item 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is West Pharmaceutical Services's deferred tax assets and other non-current assets?
- West Pharmaceutical Services (WST) reported deferred tax assets and other non-current assets of $82.8M in Q2 2026.
- How has West Pharmaceutical Services's deferred tax assets and other non-current assets changed year-over-year?
- West Pharmaceutical Services's deferred tax assets and other non-current assets increased by 17.4% year-over-year, from $70.5M to $82.8M.
- What is the long-term trend for West Pharmaceutical Services's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), West Pharmaceutical Services's deferred tax assets and other non-current assets has grown at a 27.9% compound annual growth rate (CAGR), from $23.4M to $80.1M.
Ask your AI about West Pharmaceutical Services's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude